Prognostic Factors and Survival in Non-Hodgkin's Lymphomas: The Experience of the Istituto Oncologico Romagnolo (IOR)

References

• Anderson T., De Vita V., Simon R., Berard C., Canellos G., Garvin J., Young R. Malignant Lymphoma II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2708–2721
   PubMed Web of Science ®Google Scholar
• Nabholtz I., Friedman S., Bastien M., Cuisenier J., Hor-Iot J., Guerrin J. A clinicopathological and prognostic analysis of non Hodgkin lymphoma. A study of 203 patients. Acta Oncol. 1988; 27: 489–495
   PubMed Web of Science ®Google Scholar
• Vose J., Armitage J., Weisenburger D., Bierman P., So-Rensen S., Hutchins M., Moravec D., Howe D., Dowling M., Mailliard J., Steven Johnson P., Pevnick W. The importance of age in survival of patients treated with chemotherapy for aggressive non Hodgkin's lymphoma. J. Clin. Oncol. 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P., Chastang C., Herrera A., Desaint B., Renoux M., Gaulard P., Bernard J. F., Brousse N., Boivin P. Age as the main prognostic factor in adult aggressive non Hodgkin's lymphoma. Am. J. Med. 1987; 83: 1075–1079
   PubMed Web of Science ®Google Scholar
• Dixon D., Neilan B., Jones S., Lipschitz D., Miller T., Grozea P., Wilson H. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The South-West Oncology Group experience. J. Clin. Oncol. 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• Soubeyran P., Eghbali H., Bonichon F., Trojani M., Richaud P., Hoemi B. Low grade follicular lymphomas: Analysis of prognosis in a series of 281 patients. Eur. J. Cancer 1991; 27: 1606–1613
   PubMed Web of Science ®Google Scholar
• Stein R., Greer J., Flexner J., Hainsworth J., Collins R., Macon W., Cousar J. Large cell lymphomas: Clinical and prognostic features. J. Clin. Oncol. 1990; 8: 1370–1379
   PubMed Web of Science ®Google Scholar
• Vitolo U., Bertini M., Brusamolino E., Cavallero G., Comotti B., Gallo E., Levis A., Luxi G., Meneghini V., Novero D., Orsucci L., Rota-Scalabrini D., Tarella C., Todeschini G., Viero P., Barbui T., Bernasconi C., Per-Ona G., Pileri A., Resegotti L. MACOP-B treatment in diffuse large-cell lymphoma: Identification of prognostic groups in an Italian multicenter study. J. Clin. Oncol. 1992; 10: 219–227
   PubMed Web of Science ®Google Scholar
• Dana B., Dahlberg S., Miller T., Hartsock R., Balcerzak S., Coltman C., Carden J., Hartley K., Fischer R. m-BACOD treatment for intermediate and high grade malignant lymphomas: A South West Oncology Group phase II trial. J. Clin. Oncol. 1990; 8: 1155–1162
   PubMed Web of Science ®Google Scholar
• Jagannath S., Velasquez W., Tucker S., Fuller L., McLaughlin P., Manning J., North L., Cabanillas F. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large cell lymphoma. J. Clin. Oncol. 1986; 4: 859–865
   PubMed Web of Science ®Google Scholar
• Conlan M., Bast M., Armitage J., Weisenburger D. Bone marrow involvement by non Hodgkin's lymphoma: The clinical significance of morphologic discordance between the lymph node and bone marrow. J. Clin. Oncol. 1990; 8: 1163–1172
   PubMed Web of Science ®Google Scholar
• Coiffier B., Gisselbrecht C., Vose J., Tilly H., Herbrecht R., Bosly A., Armitage J. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J. Clin. Oncol. 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar
• The Non Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non Hodgkin's lymphomas. Summary and description of a Working Formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Lennert K. Malignant Lymphomas Other Than Hodgkin's Disease. Springer-Verlag, Berlin 1981
   Google Scholar
• Boyd B., Coleman M., Papish S., Topilow A., Kopel S., Bernhardt B., Files J., Schwartz S., Gaynor M., Mc-Dermott D., Reisman A., Coleman B. COP-BLAM III: Infusional combination chemotherapy for diffuse large-cell lymphoma. J. Clin. Oncol. 1988; 6: 425–433
   PubMed Web of Science ®Google Scholar
• Miller T., Dahlberg S., Weick J., Files J., Eyre H., Pen-Dergrass K., Fisher R. Unfavorable histologies of non Hodgkin's lymphoma treated with ProMACE-CytaBOM: A group wide South West Oncology Group study. J. Clin. Oncol. 1990; 8: 1951–1958
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphomas. Ann. Int. Med. 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Gordon L., Harrington D., Andersen J., Colgan J., Glick J., Neiman R., Mann R., Resnick G., Barcos M., Gottlieb A., O'Connell M. Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with standard regimen (CHOP) for advanced diffuse non Hodgkin's lymphoma. N. Engl. J. Med. 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Schneider A., Strau D., Schluger A., Lowenthal D., Ko-Ziner B., Lee B., Wong G., Clarkson B. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate and some high grade non Hodgkin's lymphomas. J. Clin. Oncol. 1990; 8: 94–102
   PubMed Web of Science ®Google Scholar
• Fisher R., Gaynor E., Dahlberg S., Mize E., Oken M. A phase III comparison of CHOP vs m.-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high grade non Hodgkin's lymphoma: Preliminary results of SWOG-8516 (Inter group 0067), the National High Priority Lymphoma Study. Proc. ASCO 1992; 11: 315, Abstract 1067
   Google Scholar
• Portlock C. Deferral of initial therapy for advanced indolent lymphomas. Cancer Treat. Rep. 1982; 66: 417–419
   PubMedGoogle Scholar
• Rosenberg S. Validity of the Ann Arbor staging classification for the non Hodgkin's lymphomas. Cancer Treat. Rep. 1977; 61: 1023–1027
   PubMedGoogle Scholar
• Portlock C., Rosenberg S. Combination chemotherapy with cyclophosphamide, vincristine and prednisone in advanced non Hodgkin's lymphomas. Cancer 1976; 37: 1275–1282
   PubMed Web of Science ®Google Scholar
• Jones S., Grozea P., Metz E., Haut H., Stephens R., Morrison F., Butler J., Byrne G., Moon T., Fisher R., Haskins C., Coltman C. Superiority of Adria-mycin containing combination chemotherapy in the treatment of diffuse lymphoma. A South West Oncology Group study. Cancer 1979; 43: 417–425
   PubMed Web of Science ®Google Scholar
• Cohen Y., Epelbaum R., Ben-Shahar M., Ron Y., Haim N. Treatment of diffuse histiocytic and diffuse mixed non Hodgkin's lymphomas with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP). Acta Oncol. 1988; 27: 531–535
   PubMed Web of Science ®Google Scholar
• Hagberg H., Bjorkholm M., Glimelius B., Lindehalm C. H., Mellstedt H., Killander A. CHOP vs MEV for the treatment of non Hodgkin's lymphoma of unfavorable histopathology. A randomized clinical trial. Eur. J. Cancer Clin. Oncol. 1985; 21: 175–179
   PubMedGoogle Scholar
• Velasquez W., Fuller L., Jagannath S., Tucker S., North L., Hagemeister F., McLaughlin P., Swan F., Redman J., Rodriguez M., Cabanillas F. Stages I and II diffuse large-cell lymphomas: Prognostic factors and long-term results with CHOP-Bleo and radiotherapy. Blood 1991; 77: 942–947
   PubMed Web of Science ®Google Scholar
• Fisher R., Young R., Longo D., Devita V. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Semin. Oncol. 1985; XII(Suppl. 2)29–32
   Google Scholar
• Shipp M., Yeap B., Harrington D., Klatt M., Pinkus G., Jachelson M., Rosenthal D., Skarin A., Canellos G. The m-BACOD combination chemotherapy regimen in large cell lymphoma: Analysis of the completed trial and comparison with the M-BACOD regimen. J. Clin. Oncol. 1990; 8: 84–93
   PubMed Web of Science ®Google Scholar
• Karnofsky D., Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of Chemotherapeutic Agents, C. M. McLeod. Columbia University Press, New York 1949; 191–205, 191–205
   Google Scholar
• Cox D. Regression model and life table (with discussion). J. R. Stat. Soc 1972; 34: 187–222
   Google Scholar
• Kaplan E., Meier P. Non parametric estimation from incomplete observation. J. Am. Stat. Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mazza P., Gherlinzoni F., Kemna G., Poletti G., Zinzani P., Verlicchi F., Lauria F., Fiacchini M., Pileri S., Ri-Vano M., Gobbi M., Bandini G., Emiliani E., Babini L., Tura S. Clinico-pathological study on non Hodgkin's lymphomas. Haematologica 1987; 72: 351–357
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Errante D., Serraino D., Talamini R., De Cicco M., Carbone A., Monfardini S. A prospective study of a new combination chemotherapy in patients older than 70 years with unfavorable non Hodgkin's lymphoma. J. Clin. Oncol. 1992; 10: 228–236
   PubMed Web of Science ®Google Scholar
• Tura S., Mazza P., Lauria F., Fiacchini M., Pileri S., Poletti G., Gherlinzoni F., Cantore M., Bandini G. Non Hodgkin's lymphomas in leukaemic phase: Incidence, prognosis and therapeutic implications. Scand. J. Haematol. 1985; 35: 123–131
   PubMedGoogle Scholar
• Petersen F. B., Appelbaum F. R., Hill R., Fisher L., Bi-Gelow C., Sanders J., Sullivan K., Bensinger W., Whi-Terspoon R., Storb R., Clift R., Fefer A., Press O., Wei-Den P., Singer J., Thomas D., Buckner D. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle. J. Clin. Oncol. 1990; 8: 638–647
   PubMed Web of Science ®Google Scholar
• Takvorian T., Canellos G., Ritz J., Freedman A., Anderson K., Mauch P., Tarbell N., Coral F., Daley H., Yeap B., Schlossman S., Nadler L. Prolonged disease free survival after autologous bone marrow transplantation in patients with non Hodgkin's lymphomas with a poor prognosis. N. Engl. J. Med. 1987; 316: 1499–1505
   PubMed Web of Science ®Google Scholar
• Armitage J. Bone marrow transplantation in the treatment of patients with lymphoma. Blood 1989; 73: 1749–1758
   PubMed Web of Science ®Google Scholar
• Colombat P., Gorin N., Lemonnier M., Binet C., La-Porte J. P., Douay L., Desbois I., Lopez M., Lamagnere J. P., Najman A. The role of autologous bone marrow transplantation in 46 adult patients with non Hodgkin's lymphomas. J. Clin. Oncol. 1990; 8: 630–637
   PubMed Web of Science ®Google Scholar
• Weisdorf D., Andersen J., Glick J., Oken M. Survival after relapse of low grade non Hodgkin's lymphomas: Implication for marrow-transplantation. J. Clin. Oncol. 1992; 10: 942–947
   PubMed Web of Science ®Google Scholar
• Longo D., Glatstein E., Duffey P., Ihde D., Hubbard S., Fisher R., Jaffe E., Gilliom M., Young R., Devita V. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J. Clin. Oncol. 1989; 7: 1295–1302
   PubMed Web of Science ®Google Scholar
• Gherlinzoni F., Mazza P., Bocchia M., Zinzani P. L., Fiacchini M., Zanchini R., Pileri S., Tura S. Stage I high grade non Hodgkin's lymphoma: A retrospective analysis. Haematologica 1991; 76: 38–42
   PubMed Web of Science ®Google Scholar
• Tondini C., Zanini M., Lombardi F., Bengala C., Rocca A., Giardini R., Buzzoni R., Valagussa P., Bonadonna G. Combined modality treatment with primary CHOP chemotherapy followed by loco regional irradiation in stage I or II histologically aggressive non-Hodgkin's Lymphomas. J. Clin. Oncol. 1993; 11: 720–725
   PubMed Web of Science ®Google Scholar
• Foon K., Roth M., Bunn P. Interferon therapy of non Hodgkin's lymphoma. Cancer 1987; 59: 601–604
   PubMedGoogle Scholar
• Smalley R., Andersen J., Hawkins M., Bhide V., O'Con-Nell M., Oken M., Borden E. Interferon alfa combined with cytotoxic chemotherapy for patients with non Hodgkin's lymphoma. N. Engl. J. Med. 1992; 327: 1336–1341
   PubMed Web of Science ®Google Scholar
• Pettengel R., Gurney H., Radford J., Deakin P., Wilkinson P., James R., Crowther D. A randomized trial of recombinant human granulocyte colony stimulating factor to preserve dose intensity in non Hodgkin's lymphoma (NHL). Proc. ASCO 1992; 11: 319, Abstract 1083
   Google Scholar
• Blayney D., Williams S., Mortimer J., Tomita D., Horning S., Brown S., Wyres M. Neupogen (r-metHuG-CSF) ameliorates neutropenia during CHOP chemotherapy. Proc. ASCO 1992; 11: 320, Abstract 1088
   Google Scholar
• Haioun C., Lepage E., Gisselbrecht C., Coiffier B., Bosly A., Tilly H., Dupriez D., Nouvel C., Sebban C., Her-Brecht R., Gaulard P., Reyes F. Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy in first complete remission aggressive non Hodgkin's lymphoma (NHL): 1st interim analysis on 370 patients (LNH-87 protocol). Proc. ASCO 1992; 11: 316, Abstract 1071
   Google Scholar
• Nademanee A., Schmidt G., Sniecinsky I., Snyder D., O'Donnell M., Parker P., Stein A., Smith E., Stepan D., Molina A., Taguchi J., Margolin K., Somlo G., For-Man S. G-CSF primed peripheral blood stem cell autografts in patients with advanced lymphoid malignancies. Proc. ASCO 1992; 11: 317, Abstract 1075
   Google Scholar
• Vose J., Bierman P., Anderson J., Kessinger A., Pierson J., Coccia P., Gordon B., Reed E., Armitage J. High dose chemotherapy with hematopoietic stem cell rescue for non Hodgkin's lymphoma (NHL): Evaluation of event free survival based on histologic subtype and rescue product. Proc. ASCO 1992; 11: 320, Abstract 1080
   Google Scholar
• Miller T., Grogan T., Dalton W., Spier C., Scheper R., Salmon S. p-Glicoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 1991; 9: 17–24
   PubMed Web of Science ®Google Scholar